Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G.

Abstract	An 18-month-old black girl had progressive truncal ataxia, opsoclonus, and multifocal myoclonus associated with a nonresectable abdominal ganglioneuroblastoma. Before chemotherapy, she received intravenously administered IgG, 1 gm/kg, for 2 days; within 48 hours of the first dose, there was significant improvement of the opsoclonus-myoclonus and ataxia. She required a 1 gm/kg maintenance dose every 4 to 6 weeks for a total of 12 doses, but is now free of symptomatic after 2 years with no therapy.
Authors	M J Petruzzi, P A de Alarcon
Journal	The Journal of pediatrics (J Pediatr) Vol. 127 Issue 2 Pg. 328-9 (Aug 1995) ISSN: 0022-3476 [Print] United States
PMID	7636667 (Publication Type: Case Reports, Journal Article)
Chemical References	Immunoglobulins, Intravenous
Topics	Adrenal Gland Neoplasms (complications) Female Ganglioneuroblastoma (complications) Humans Immunoglobulins, Intravenous Infant Myoclonus (etiology, therapy) Ocular Motility Disorders (etiology, therapy) Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!